EMMA 2016 | Allogeneic transplant in multiple myeloma: who should receive it and the future of transplant
Heinz Ludwig, MD of Wilhelminen Cancer Research Institute, Vienna, Austria discusses the role of allogeneic stem cell transplantation in multiple myeloma (MM) with Joan Bladé, MD of the Hospital Clinic, Barcelona, Spain at the 2016 European Multiple Myeloma Academy (EMMA) in Madrid, Spain. The first topic is on which patients should be offered an allogeneic stem cell transplant in 2016. The next point of discussion is what to do if the allogeneic transplant is failing. Prof. Ludwig discusses the new approach of inserting suicide genes into the T-cells of the donor, which helps modulate severe graft-versus-host-disease (GvHD). Prof. Bladé highlights that GvHD is the main problem in allogeneic transplant, which occurs in 20–30% of cases and is the main cause of death. Therefore, the conditioning and the management of GvHD needs to be improved. The experts explore data on the use of allogeneic transplant after relapsed or refractory disease as well as that on allogeneic vs autologous transplant in relapsed/refractory patients.
This programme has been supported by Celgene and Amgen through an unrestricted educational grant to the Video Journal of Hematological Oncology.
- allogeneic stem cell transplant
- autologous stem cell transplant
- CAR T-cells
- checkpoint inhibitors
- complete remission
- induction therapy
- partial response
- progressive disease
- radiation therapy
- suicide genes
- targeted therapy
- tumor burden
Get great new content delivered to your inboxSign up